



RECEIVED

MAR 22 2002 #6

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re: APPLICATION OF:

Group Art Unit: 1624

Siev et al.

: Examiner:
BALASUBRAMANIAN, V.

Application No.: 09/905,644

: Certificate of Mailing Under C.F.R.
\$1.8

Filed: July 13, 2001

: I hereby certify that this
correspondence and all marked
: attachments are being deposited with
the United States Postal Service as
: first class mail in an envelope
addressed to: Assistant Commissioner
: for Patents, Washington, D.C. 20231
on March 11, 2002.

Title: NOVEL NON-COVALENT
THROMBIN INHIBITORS

By: _____

Kim A. Cabello
Kim A. Cabello

RESPONSE

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated January 9, 2002,
Applicants make the following response and have the following
remarks:

REMARKS

Applicants note that the Office Action mailed January 9,
2002 set an initial one-month period for response. Applicants
note that submitted herewith is a Petition under 37 C.F.R.
\$1.136 for a one month extension of time and a check which

includes the required fee. With the granting of this petition, the time period in which to submit a timely response to the Office Action mailed January 9, 2002 will be extended to March 11, 2002, since March 9, 2002 was a Saturday.

Applicants note that the present Office Action was mailed to the undersigned Applicants' attorney at an incorrect address which was not the address set forth in the Power of Attorney for this application. On March 11, 2002, the undersigned Applicants' attorney notified the Examiner of this error and, at the Examiner's request is submitting a Change of Address form.

In the office action mailed January 9, 2002, the Examiner required restriction to one of the following inventions:

I: Claims 1 to 49, drawn to compounds of formula I where $Q = N$, compositions and methods of use; and

II: Claims 1 to 49, drawn to compounds of formula I where $Q = R_y$, compounds and methods of use.

In response to the above restriction requirement, applicants provisionally elect the invention of Group II, namely those compounds where $Q = R_y$ to give a pyridinone group with traverse.

Applicants submit that, although the invention of Group I is directed to compounds of formula I having a pyrazinone group and the invention of Group II is directed to compounds of formula having a pyridinone group, the compounds are sufficiently related so as to be properly examinable together without undue burden on the Examiner. Accordingly, Applicants

request that the Examiner reconsider his restriction requirement and withdraw it and rejoin the two groups for examination.

If the Examiner believes that a telephonic interview would expedite prosecution of this application, he is encouraged to telephone the undersigned Applicants' attorney.

If the fee submitted herewith is incorrect or if any additional fee is due in connection with this submission, please charge any such fee or credit any over payment to Deposit Account No. 03-3975.

Respectfully submitted,
Pillsbury Winthrop LLP

By: 

Suzanne L. Biggs
Reg. No.: 30,158
Tel. No.: (858) 509-4095
Fax No.: (858) 509-4010

Pillsbury Winthrop LLP
50 Fremont Street
P. O. Box 7880
San Francisco, CA 94105